Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ChimeriVax-West Nile Virus Live-Attenuated Vaccine: Preclinical Evaluation of Safety, Immunogenicity, and Efficacy

26 Oct 2004

Abstract excerpt

The availability of ChimeriVax vaccine technology for delivery of flavivirus protective antigens at the time West Nile (WN) virus was first detected in North America in 1999 contributed to the rapid development of the vaccine candidate against WN virus described here. ChimeriVax-Japanese encephalitis (JE), the first live- attenuated vaccine developed with this technology has successfully undergone phase I and II...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Malaria Research and Control
Share to Mosquito-borne diseases and control
Share to Viral Infections and Vectors

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 15507637
DOI: 10.1128/jvi.78.22.12497-12507.2004

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ChimeriVax-West Nile Virus Live-Attenuated Vaccine: Preclinical Evaluation of Safety, Immunogenicity, and EfficacyPMID 15507637Read ↗

Prospects for Development of a Vaccine against the West Nile VirusSemantic proximity Read ↗

Development of Antigen-Specific Memory CD8+ T Cells Following Live-Attenuated Chimeric West Nile Virus VaccinationSemantic proximity Read ↗

West Nile virus/dengue type 4 virus chimeras that are reduced in neurovirulence and peripheral virulence without loss of immunogenicity or protective efficacySemantic proximity Read ↗

Protective Efficacy of a Chimeric Insect-Specific Flavivirus Vaccine against West Nile VirusSemantic proximity Read ↗

Molecular Basis for Attenuation of Neurovirulence of a Yellow Fever Virus/Japanese Encephalitis Virus Chimera Vaccine (ChimeriVax-JE)Semantic proximity Read ↗

Japanese encephalitis vaccines: Immunogenicity, protective efficacy, effectiveness, and impact on the burden of disease.Semantic proximity Read ↗

Immunogenicity, Genetic Stability, and Protective Efficacy of a Recombinant, Chimeric Yellow Fever-Japanese Encephalitis Virus (ChimeriVax-JE) as a Live, Attenuated Vaccine Candidate against Japanese EncephalitisSemantic proximity Read ↗

Inactivated West Nile Virus (WNV) vaccine, Duvaxyn WNV, protects against a highly neuroinvasive lineage 2 WNV strain in miceSemantic proximity Read ↗

Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis virusesSemantic proximity Read ↗

A yellow fever 17D and Usutu virus chimera with rationally designed mutations in the envelope protein is lethal in an Ifnar-/- mouse model.Semantic proximity Read ↗

Next generation live-attenuated yellow fever vaccine candidate: Safety and immuno-efficacy in small animal modelsSemantic proximity Read ↗

Development and Characterization of Yellow Fever Virus Vaccine Strain 17DD-Based Chimeric Tick-Borne Encephalitis VirusSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.